Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | LAP3 | P28838 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633090 | 1.00 | MME (0.51) | MMESLC1A3SLC1A2CPA1SLC1A1 | |
| SCHEMBL4633086 | 1.00 | MME (0.51) | MMESLC1A3SLC1A2CPA1SLC1A1 | |
| SCHEMBL8669433 | 0.84 | SLC1A1 (0.47) | SLC1A1MMP1MMP2MMP3MMP9 | |
| SCHEMBL5552692 | 0.83 | SLC1A3 (0.48) | MMESLC1A3SLC1A2CPA1SLC1A1 | |
| SCHEMBL7453163 | 0.83 | MME (0.54) | MMESLC1A3SLC1A2KMT2A | |
| SCHEMBL7422303 | 0.82 | MME (0.38) | MMESLC1A3SLC1A2SLC1A1MMP2 | |
| SCHEMBL7099851 | 0.82 | MMP1 (0.40) | MMESLC1A3SLC1A2SLC1A1SLC7A5 | |
| SCHEMBL22432286 | 0.82 | MMP1 (0.40) | MMESLC1A3SLC1A2SLC1A1SLC7A5 | |
| SCHEMBL2921467 | 0.82 | SLC1A3 (0.47) | MMESLC1A3SLC1A2CPA1SLC1A1 | |
| SCHEMBL2637671 | 0.80 | SLC1A3 (0.46) | MMESLC1A3SLC1A2CPA1LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008104755-A1 | SUCCINATE DERIVATIVES AND THEIR THERAPEUTIC USE | SERENTIS LIMITED (GB) | 2008-09-04 | — | — | WO | disclosed |
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | SERENTIS LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | MMP8, CUTA, MMP1 | MME 540/4885SLC1A3 4011/4885SLC1A2 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.